Reduction of in vivo coronary artery thrombosis by the novel thromboxane antagonist (3R)-3-(4-Fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazolepropanoic acid - Fiedler, V B; Perzborn, E; Seuter, F; Rosentreter, U; Boshagen, H (Arzneim Forsch Drug Res, 1989)